HMNC Brain Health, a clinical-stage neuroscience company based in Munich, has announced a $50 million first closing of its Series B financing, led by MEDICE – The Health Family with participation from existing investor The Maschmeyer Group.
The funding will support late-stage development of the company’s mental health pipeline, including Phase 3-readiness activities for Ketabon (KET01) and Nelivabon (BH-200). HMNC is developing KET01 as an oral prolonged-release ketamine treatment for treatment-resistant depression, while BH-200 is being advanced as a biomarker-guided therapy for biologically defined depressive disorders.
Alongside the financing, MEDICE has entered a strategic licensing agreement for the European commercialization of KET01. The deal gives MEDICE exclusive commercialization rights in Europe and makes HMNC eligible for tiered double-digit royalties and success-based milestone payments.
The announcement highlights continued investor and industry interest in neuropsychiatry, particularly in therapies aimed at treatment-resistant depression and precision approaches to mental health treatment.
The funding will support late-stage development of the company’s mental health pipeline, including Phase 3-readiness activities for Ketabon (KET01) and Nelivabon (BH-200). HMNC is developing KET01 as an oral prolonged-release ketamine treatment for treatment-resistant depression, while BH-200 is being advanced as a biomarker-guided therapy for biologically defined depressive disorders.
Alongside the financing, MEDICE has entered a strategic licensing agreement for the European commercialization of KET01. The deal gives MEDICE exclusive commercialization rights in Europe and makes HMNC eligible for tiered double-digit royalties and success-based milestone payments.
The announcement highlights continued investor and industry interest in neuropsychiatry, particularly in therapies aimed at treatment-resistant depression and precision approaches to mental health treatment.